Plasma phospholipase A2 activity may serve as a novel diagnostic biomarker for the diagnosis of breast cancer

Abstract

Abstract. Previous studies have indicated that phospholipase A2 (PLA2) may be associated with tumorigenesis in human tissues. The present study aimed to investigate the association between plasma PLA2 activity and the breast cancer (BC) status of patients. Increased plasma PLA2 activity was detected in patients with breast cancer when compared with healthy controls. Plasma samples were obtained from patients with BC (n=169), patients with benign disease (BD; n=80) and healthy controls (n=81). PLA2 activity was assessed using a quantitative fluorescent assay with selective inhibitors. It was demonstrated that increased PLA2 and secretory PLA2 (sPLA2) activity was associated with tumor stage, particularly in patients with late-stage disease. Additionally, smoking, alcohol consumption, body mass index (BMI) and age of patients did not have a significant effect on PLA2 activity. Analysis of receiver operating characteristic curves revealed that plasma PLA2 and sPLA2 activities were increased in BC patients compared with healthy controls. It was concluded that plasma PLA2 activity may serve as a biomarker for patients with BC.

Phosphoproteomics identify arachidonic-acid-regulated signal transduction pathways modulating macrophage functions with implications for ovarian cancer

“…Our data suggest that pharmacological inhibition of PLA2G2A might be therapeutically beneficial in OC, although direct experimental evidence is lacking at this point. Furthermore, PLA2G2A might be a useful prognostic marker, as suggested for breast cancer 102 , a question to be addressed in future biomarker studies.…”

Resveratrol Action on Lipid Metabolism in Cancer

“…Eicosanoids, including prostaglandins and leukotrienes, are products of local cell type-specific metabolism of ARA and form an important class of bioactive lipid mediators, playing critical roles in diverse physiological and pathological processes, such as inflammation and cancer [155,156,157,158]. In cancer patients, the level of PLA2 elevates significantly [159,160,161]. RES (5 mg/kg) inhibited the p38 MAPK-–cytosolic phospholipase A2–arachidonic acid–TxA2–[Ca +2 ]i cascade, resulting in the inhibition of phospholipase C and/or protein kinase C (PKC) activation and significant prolongation of platelet plug formation in mice [162].…”

Analytical Platforms for the Determination of Phospholipid Turnover in Breast Cancer Tissue: Role of Phospholipase Activity in Breast Cancer Development

“…Each of them is involved in the regulation of important cellular functions, and their up-or down-regulation is postulated to be associated with the progression of the disease. This is the reason why this group of enzymes are considered as target molecules in the anti-tumor therapy [ 26 ]. The signaling role of PLA 2 and the products of its activity is demonstrated in cancer cell lines, in which the inhibition of the PLA 2 activity increases the sensitivity towards chemotherapy of breast and cervical epithelial cell line Ect/E6E7 [ 27 ].…”

“…In these studies, the enzyme concentration was determined from tissue homogenates by radioimmune assay and immunohistochemistry, respectively. In addition to the overexpression of sPLA 2 in the BC tissue, plasma and sPLA 2 were also considered as the diagnostic markers for the BC, in particular in patients in later diseases stages [ 26 ].…”

“…Based on the changes in fluorescence intensity, the enzyme activity can be determined. Although some critical points could be raised against the application of a non-natural substrate, this approach was used in the study of BC biomarkers in plasma [ 26 ]. In case where natural substrates are used for the assessment of the PLA 2 activity, lipid extraction and separation are usually applied, and the concentration of either substrate or products of the PLA 2 activity (FFA or LPL) can be determined by LC-MS or MS only.…”